Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
earnings forward grow growth looking percent products share
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.
forward join leadership role senior vital
He is very well-prepared for the vital role he will play, and I look forward to having him join our senior leadership team.
access affordable assistance earthquake ease employees ensure essential forward gave groups halt health hurricane improve offered patients save seniors share six spread stepped suffering urgent year
In a year of urgent needs, Lilly and its employees stepped forward with extraordinary efforts. To ease the suffering of hurricane and earthquake victims, we gave essential medicines, cash, and supplies. To ensure that seniors and low-income patients had affordable access to drugs, we offered six patient assistance programs. And to halt the spread of multi-drug-resistant tuberculosis, we partnered with the World Health Organizations and other groups to share expertise, improve treatment, and save lives.
expectation overall
I think there is an overall unreasonable expectation right now that there is such a thing as a risk-free drug.
commitment execution faster grow quarter rate reflect results sales strong
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
lives saving thousands
We're going to be saving hundreds of thousands of lives with this product,
completion confidence continued future high initiation level rapid reflect share
The rapid completion of the share repurchase program, coupled with the initiation of a new program, reflect the board's continued high level of confidence in the future of the company.
data erosion months nearly product prozac sales severe
With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry,
built class financial reputation sound
Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations.
economy growing region resilient seeing seems
We are seeing a very resilient economy and one that seems to be growing in every part of the world. Just about every region is growing and it's very encouraging.
access affordable best care disaster ensure founders health nearly needing patients people survivors values whether
Whether they are patients needing access to affordable health care or survivors of a disaster, we do our best to ensure that people in need are not forgotten. Our founders established these values nearly 130 years ago, and we live by them today.
adjusted anticipate average compared consensus deliver double earnings expect expected fact forecast given growth major nearly patent per rate represents rest share street sustained uniquely wall
Given our products, pipeline, and the fact that we expect no major patent expirations for the rest of this decade, Lilly is uniquely positioned to deliver sustained earnings growth. For 2006, we anticipate earnings per share of $3.10 to $3.20, which represents 8% to 12% growth compared with expected 2005 adjusted earnings. This growth rate is nearly double the average Wall Street consensus forecast for large-cap pharmaceutical companies.
address bring closely committing company continue deliver fda innovative medicines necessary order patients promise quickly resources work
I am committing all the necessary resources of the company to address these issues, ... We will continue to work closely with the FDA in order to deliver on our promise to bring these innovative new medicines to patients as quickly as possible.
building importance launching pipeline quarter strong
While the first quarter was a challenging quarter, it underscores the importance of building a strong pipeline and effectively launching new products,